急性痛 - 市場考察、疫学、市場予測（2034年）

主なハイライト

• 急性痛市場は、既存薬の普及、予測される市場投入、認知度の向上により、大幅なプラス成長が見込まれます。
• 急性痛の新たなパイプラインにはさまざまな有望な治療薬が含まれ、予測期間（2024年～2034年）に主要7市場の急性痛市場に参入する見込みです。
• 米国は、欧州4ヶ国（ドイツ、スペイン、イタリア、フランス）、英国、日本と比較して、最大の急性痛の市場規模を占めています。
• International Association for the Study of Pain（IASP）は、急性痛を、脅威や疾患を知らせる突然の鋭い痛みと定義しています。急性痛は、怪我、手術、疾患、外傷、医療処置によって生じ、通常、数分から6ヵ月未満持続し、治療や治癒によって治まります。
• 2023年、米国では術後痛、外傷痛、急性疾患が、それぞれ急性痛と診断された症例の40%以下、40%以下、20%以下を 占めています。
• 2024年2月、AFT Pharmaceuticalsは、ライセンシーであるHikma Pharmaceuticalsを通じて、同社の鎮痛薬の静脈内投与型であるMaxigesic IVを米国で上市したことを明らかにしました。
• 承認されている急性痛治療薬には、Hyloris Pharmaceuticals/AFT Pharmaceuticals（MAXIGESIC）、Formosa Pharmaceuticals（APP13007）などがあります。
• 新薬としては、Vertex Pharmaceuticals（suzetrigine）、Taiwan Liposome Company（ropivacaine liposomal）、Vivozon（opiranserin）などがあります。

急性痛市場の見通し

Trevena、Innocoll Pharmaceuticals、Esteve、Kowa Pharmaceuticals、Mundi Pharmaなどの主要な急性痛企業は、それぞれ異なる臨床開発段階で主要候補薬を評価しています。これらの企業は、急性痛の治療薬として自社製品を研究することを目指しています。

• 主要7市場の急性痛の新たなパイプラインには、予測期間に急性痛市場に参入することが予測されるさまざまな有望な治療法が含まれています。2032年までに、すべての治療法の中でもっとも高い収益を上げると予測されるのはUBRELVYです。
• 新たな急性痛治療薬の中でもっとも収益が低いのはVX-548とTLC590になると予測されます。
• 急性痛市場の発展は、より優れた臨床プロファイルを持つ新治療薬の参入、治療薬の市場浸透の増加、研究開発の活発化、疾患に対する理解の深まり、目前に迫った薬剤の上市などによって促進されると予測されます。

当レポートでは、急性痛の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 急性痛市場の概要

• 急性痛の市場シェアの分布：薬剤クラス別（2020年）
• 急性痛の市場シェアの分布：薬剤クラス別（2034年）

第4章 急性痛のエグゼクティブサマリー

第5章 重要な出来事

第6章 急性痛の疫学と市場調査手法

第7章 疾患の背景と概要：急性痛

• イントロダクション
• 急性痛と慢性痛の違い
• 急性痛から慢性痛への移行
• 急性痛の種類
• 兆候と症状
• 原因
• 急性痛の病態生理学
• 診断
• 治療

第8章 急性痛のペイシェントジャーニー

第9章 急性痛の疫学と患者人口

• 主な調査結果
• 前提条件と根拠：急性痛
• 主要7市場の急性痛の総罹患者数
• 主要7市場の急性痛の診断された総罹患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 上市済みの急性痛治療薬

• 主な競合
• POSIMIR（bupivacaine solution）：Durect Corporation
• SEGLENTIS（celecoxib and tramadol hydrochloride）：Esteve/Kowa Pharmaceuticals/Mundipharma
• DSUVIA（sufentanil）：AcelRx Pharmaceuticals
• ZYNRELEF（bupivacaine and meloxicam）：Heron Therapeutics
• UBRELVY（ubrogepant）：Allergan

第11章 新たな急性痛治療薬

• 主な競合
• Opiranserin（VVZ-149）：Vivozon
• TLC590（ropivacaine liposomal）：Taiwan Liposome Company（TLC）
• VX-548（suzetrigine）：Vertex Pharmaceuticals

第12章 急性痛市場：主要7市場の分析

• 主な調査結果
• 急性痛市場の見通し
• コンジョイント分析
• 急性痛市場の予測の前提条件
• 主要7市場の急性痛の総市場規模
• 主要7市場の急性痛の市場規模：治療法別
• 米国
  • 米国の急性痛の総市場規模
  • 米国の急性痛の市場規模：治療法別
• 欧州4ヶ国・英国
  • 欧州4ヶ国・英国の急性痛の総市場規模
  • 欧州4ヶ国・英国の急性痛の市場規模：治療法別
• 日本
  • 日本の急性痛の総市場規模
  • 日本の急性痛の市場規模：治療法別

第13章 急性痛KOLの見解

第14章 急性痛のアンメットニーズ

第15章 急性痛のSWOT分析

第16章 急性痛市場へのアクセスと償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本
• 急性痛における償還シナリオと主なHTAの決定

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

List of Tables

• Table 1: Summary of Acute Pain Market, and Epidemiology (2019-2032)
• Table 2: Acute vs. Chronic Pain in the ED
• Table 3: Treatment guidelines for Acute Pain
• Table 4: Total Incidence of Acute Pain in the 7MM in millions (2019-2032)
• Table 5: Total Diagnosed Incident Cases of Acute Pain in the 7MM in millions (2019-2032)
• Table 6: Type-specific Diagnosed Incident Cases of Acute Pain in the 7MM in millions (2019-2032)
• Table 7: Severity-specific Diagnosed Incident Cases of Acute Pain in the 7MM in millions (2019-2032)
• Table 8: Total Treated Cases of Acute Pain in the 7MM in millions (2019-2032)
• Table 9: Total Incidence of Acute Pain in the United States in millions (2019-2032)
• Table 10: Total Diagnosed Incident Cases of Acute Pain in the United States in millions (2019-2032)
• Table 11: Type-specific Diagnosed Incident Cases of Acute Pain in the United States in millions (2019-2032)
• Table 12: Severity-specific Diagnosed Incident Cases of Acute Pain in the United States (in millions (2019-2032)
• Table 13: Total Treated Cases of Acute Pain in the United States in millions (2019-2032)
• Table 14: Total Incidence of Acute Pain in EU4 and the UK in millions (2019-2032)
• Table 15: Total Diagnosed Incident Cases of Acute Pain in EU4 and the UK in millions (2019-2032)
• Table 16: Type-specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK in millions (2019-2032)
• Table 17: Severity-specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK in millions (2019-2032)
• Table 18: Total Treated Cases of Acute Pain in EU4 and the UK in millions (2019-2032)
• Table 19: Total Incidence of Acute Pain in Japan in millions (2019-2032)
• Table 20: Total Diagnosed Incident Cases of Acute Pain in Japan in millions (2019-2032)
• Table 21: Type-specific Diagnosed Incident Cases of Acute Pain in Japan in millions (2019-2032)
• Table 22: Severity-specific Diagnosed Incident Cases of Acute Pain in the United States (in millions (2019-2032)
• Table 23: Total Treated Cases of Acute Pain in Japan in millions (2019-2032)
• Table 24: POSIMIR (bupivacaine solution), Clinical Trial Description, 2022
• Table 25: XARACOLL (bupivacaine), Clinical Trial Description, 2022
• Table 26: EXPAREL (bupivacaine liposome injectable suspension), Clinical Trial Description, 2022
• Table 27: SEGLENTIS (celecoxib and tramadol hydrochloride), Clinical Trial Description, 2022
• Table 28: DSUVIA (sufentanil), Clinical Trial Description, 2022
• Table 29: ZYNRELEF (bupivacaine and meloxicam), Clinical Trial Description, 2022
• Table 30: OLINVYK (oliceridine), Clinical Trial Description, 2022
• Table 31: UBRELVY (ubrogepant), Clinical Trial Description, 2022
• Table 32: ANJESO (meloxicam), Clinical Trial Description, 2022
• Table 33: DEXTENZA (dexamethasone ophthalmic insert), Clinical Trial Description, 2022
• Table 34: INVELTYS (loteprednol etabonate/KPI-121), Clinical Trial Description, 2022
• Table 35: Comparison of Emerging Drugs Under Development
• Table 36: MAXIGESIC IV (paracetamol + ibuprofen), Clinical Trial Description, 2022
• Table 37: APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), Clinical Trial Description, 2022
• Table 38: Opiranserin (VVZ-149), Clinical Trial Description, 2022
• Table 39: Vocacapsaicin (CA-008), Clinical Trial Description, 2022
• Table 40: VX-548, Clinical Trial Description, 2022
• Table 41: TLC590, Clinical Trial Description, 2022
• Table 42: CL-108, Clinical Trial Description, 2022
• Table 43: CL-108, Clinical Trial Description, 2022
• Table 44: CL-H1T, Clinical Trial Description, 2022
• Table 45: ZALVISO (sufentanil), Clinical Trial Description, 2022
• Table 46: TPU-006, Clinical Trial Description, 2022
• Table 47: NVK-009, Clinical Trial Description, 2022
• Table 48: Key Market Forecast Assumptions for MAXIGESIC IV
• Table 49: Key Market Forecast Assumptions for PENTHROX (methoxyflurane)
• Table 50: Key Market Forecast Assumptions for VX-548
• Table 51: Key Market Forecast Assumptions for APP13007
• Table 52: Key Market Forecast Assumptions for TLC590
• Table 53: Key Market Forecast Assumptions for CA-008
• Table 54: Key Market Forecast Assumptions for Opiranserin (VVZ-149)
• Table 55: Total Acute Pain Market Size in the 7MM, in USD million (2019-2032)
• Table 56: Acute Pain Market Size by Therapies in the 7MM, USD million (2019-2032)
• Table 57: Total Acute Pain Market Size in the United States, in USD million (2019-2032)
• Table 58: Acute Pain Market Size by Therapies in the United States, USD million (2019-2032)
• Table 59: Total Acute Pain Market Size in EU4 and the UK, in USD million (2019-2032)
• Table 60: Acute Pain Market Size by Therapies in EU4 and the UK, USD million (2019-2032)
• Table 61: Total Acute Pain Market Size in Japan, in USD million (2019-2032)
• Table 62: Acute Pain Market Size by Therapies in Japan, USD million (2019-2032)

List of Figures

• Figure 1: Epidemiology and Market Methodology
• Figure 2: Types of Pain
• Figure 3: Types of Pain Based on Duration
• Figure 4: Progression of Acute pain to Chronic Pain
• Figure 5: Signs and Symptoms of Acute Pain
• Figure 6: Causes of Acute Pain
• Figure 7: Diagnostic algorithm for pain assessment
• Figure 8: WHO Pain Relief Ladder
• Figure 9: Treatment Algorithm for Acute Post-operative Pain
• Figure 10: Total Incidence of Acute Pain in the 7MM (2019-2032)
• Figure 11: Total Diagnosed Incident Cases of Acute Pain in the 7MM (2019-2032)
• Figure 12: Type-specific Diagnosed Incident Cases of Acute Pain in the 7MM (2019-2032)
• Figure 13: Severity-specific Diagnosed Incident Cases of Acute Pain in the 7MM (2019-2032)
• Figure 14: Total Treated Cases of Acute Pain in the 7MM (2019-2032)
• Figure 15: Total Incidence of Acute Pain in the United States (2019-2032)
• Figure 16: Total Diagnosed Incident Cases of Acute Pain in the United States (2019-2032)
• Figure 17: Type-specific Diagnosed Incident Cases of Acute Pain in the United States (2019-2032)
• Figure 18: Severity-specific Diagnosed Incident Cases of Acute Pain in the United States (2019-2032)
• Figure 19: Total Treated Cases of Acute Pain in the United States (2019-2032)
• Figure 20: Total Incidence of Acute Pain in EU4 and the UK (2019-2032)
• Figure 21: Total Diagnosed Incident Cases of Acute Pain in EU4 and the UK (2019-2032)
• Figure 22: Type-specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK (2019-2032)
• Figure 23: Severity-specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK (2019-2032)
• Figure 24: Total Treated Cases of Acute Pain in EU4 and the UK (2019-2032)
• Figure 25: Total Incidence of Acute Pain in Japan (2019-2032)
• Figure 26: Total Diagnosed Incident Cases of Acute Pain in Japan (2019-2032)
• Figure 27: Type-specific Diagnosed Incident Cases of Acute Pain in Japan (2019-2032)
• Figure 28: Severity-specific Diagnosed Incident Cases of Acute Pain in Japan (2019-2032)
• Figure 29: Total Treated Cases of Acute Pain in Japan (2019-2032)
• Figure 30: Total Acute Pain Market Size in the 7MM, USD million (2019-2032)
• Figure 31: Acute Pain Market Size by Therapies in the 7MM, USD million (2019-2032)
• Figure 32: Total Acute Pain Market Size in the United States, USD million (2019-2032)
• Figure 33: Acute Pain Market Size by Therapies in the United States, USD million (2019-2032)
• Figure 34: Total Acute Pain Market Size in EU4 and the UK, USD million (2019-2032)
• Figure 35: Acute Pain Market Size by Therapies in EU4 and the UK, USD million (2019-2032)
• Figure 36: Total Acute Pain Market Size in Japan, USD million (2019-2032)
• Figure 37: Acute Pain Market Size by Therapies in Japan, USD million (2019-2032)

Key Highlights:

• The Acute Pain market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch, and raised awareness.
• The emerging pipeline of acute pain contains various promising therapies expected to enter the 7MM Acute Pain market during the forecast period (2024-2034).
• The United States accounts for the largest Acute Pain market size, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• The International Association for the Study of Pain (IASP) defines acute pain as sudden, sharp pain signaling a threat or disease. It arises from injury, surgery, illness, trauma, or medical procedures, typically lasting from minutes to less than 6 months and subsiding with treatment or healing.
• In 2023, postoperative pain, trauma pain, and acute medical illness accounted for ~40%, ~40%, and ~20% of diagnosed incident cases of acute pain in the United States, respectively.
• In February 2024, AFT Pharmaceuticals disclosed the launch of Maxigesic IV, the intravenous variant of its pain relief medication, in the United States through its licensee, Hikma Pharmaceuticals.
• Some of the approved Acute Pain therapies include Hyloris Pharmaceuticals/AFT Pharmaceuticals (MAXIGESIC), Formosa Pharmaceuticals (APP13007), and others.
• Emerging Drugs are - Vertex Pharmaceuticals (suzetrigine), Taiwan Liposome Company (ropivacaine liposomal), Vivozon (opiranserin) and others.
• DelveInsight's "Acute Pain Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
• Acute Pain market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Acute Pain market size from 2020 to 2034. The report also covers current Acute Pain treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Acute Pain Treatment Market

Acute Pain Overview, Country-Specific Treatment Guidelines and Diagnosis

Acute pain is an umbrella term, but the most common symptoms associated with acute pain include fatigue, flu-like symptoms, insomnia, anxiety, burning, etc. Nociceptive pain is usually acute and develops in response to a specific situation. It disappears as the affected body part heals. For example, nociceptive pain from a broken ankle gets better as the ankle heals.

Diagnosis of acute pain is made using pain assessment scales, which include VAS, VRS, NPRS, MPQ, BPI, etc. Doctors diagnose the pain by discussing symptoms, the intensity and location of pain, and the history of injury, surgery, or illness. Young patients may be asked to rate their pain intensity using the faces of the pain scale.

Additional diagnostic tests might include Blood Tests, X-rays, CT scans, MRI, Ultrasounds, Dye-injection studies, and Nerve conduction studies.

Acute Pain Treatment

WHO recommends a 3-step "Pain relief ladder" for pain management, starting with non-opioid approaches, then progressing to low-dose opioids with or without adjunct therapies, and finally, higher doses or more potent opioids for moderate-to-severe pain. Variations include a "fast-track" approach for intense acute pain, movement up or down the ladder based on disease progression or healing, and a 4th step involving invasive procedures like nerve blocks and spinal stimulators.

Acute Pain Epidemiology

The Acute Pain epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Acute Pain epidemiology is segmented with detailed insights into the total incident cases, total diagnosed cases, type-specific cases, severity-specific cases, and total treated cases of acute pain.

• In 2023, total severity-specific diagnosed incident cases of acute pain in the United States comprised ~40%, ~50%, and ~10% cases for mild, moderate, and severe, respectively.
• Postoperative pain represented around 40% of the type-specific diagnosed incident cases of acute pain in the United States in 2023, making it the most prevalent category.
• DelveInsight estimates that the total incidence of cases of acute pain in the United States is expected to increase in the forecasted period.

Acute Pain Drug Chapter

The drug chapter segment of the Acute Pain market report encloses a detailed analysis of Acute Pain marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Acute Pain pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Acute Pain Drugs

POSIMIR (bupivacaine solution): Durect Corporation

POSIMIR (bupivacaine solution) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. POSIMIR contains more bupivacaine than any other approved single-dose sustained-release bupivacaine product. POSIMIR is administered into the subacromial space under direct arthroscopic visualization at the end of the surgery, where it continuously releases bupivacaine for 72 hours or more.

ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) is a fixed-dose combination of the local anesthetic bupivacaine with the non-steroidal anti-inflammatory drug (NSAID) meloxicam. The drug is approved in Europe, while an NDA in the US has been approved in January 2024. ZYNRELEF is indicated to treat somatic-postoperative pain from small- to medium-sized surgical wounds in adults.

Emerging Acute Pain Drugs

VVZ-149 (opiranserin): Vivozon

Opiranserin (VVZ-149) for injection, developed by Vivozon, is a pioneering non-narcotic analgesic targeting postoperative pain. It seeks to replace opioid analgesics by offering a safe and efficient pain management solution. Opiranserin is a multi-target drug acting on GlyT2 and 5HT2a, key in pain signal generation and regulation, providing analgesia in both the central and peripheral nervous systems. Currently, VVZ-149 is in the Phase III clinical stage of development. In February 2023, Vivozon Pharmaceuticals announced that the results of domestic Phase III clinical trials of the non-narcotic painkiller VVZ-149 (opiranserin) confirmed the analgesic efficacy and safety.

TLC590 (ropivacaine liposomal): Taiwan Liposome Company (TLC)

TLC590 (ropivacaine liposomal) is a non-opioid, BioSeizer sustained release formulation of ropivacaine designed to prolong the retention time of ropivacaine around the injection site as a drug depot, simultaneously extending its therapeutic period and reducing unwanted systemic exposure. Currently, TLC590 is being investigated in a Phase II/III clinical trial for postsurgical pain management following inguinal hernia repair.

Acute Pain Market Outlook

Key Acute Pain companies, such as Trevena, Innocoll Pharmaceuticals, Esteve, Kowa Pharmaceuticals, Mundi Pharma, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Acute Pain.

• The emerging pipeline of acute pain contains various promising therapies expected to enter the 7MM Acute Pain market during the forecast period. By 2032, among all the therapies, the highest revenue is expected to be generated by UBRELVY.
• Among all the emerging Acute Pain therapies, the lowest revenue is expected to be generated by VX-548 and TLC590.
• Growth of the acute pain market is expected to be mainly driven by the entry of novel therapies with better clinical profiles, an increase in market penetration of therapies, an upsurge in research and development, an enriched understanding of the disease, and imminent launches of the drugs.

Acute Pain Drugs Uptake

This section focuses on the uptake rate of potential Acute Pain drugs expected to be launched in the Acute Pain market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Acute Pain Activities

The Acute Pain market report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Acute Pain market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Pain emerging therapies.

Acute Pain KOL Views

To keep up with the real-world scenario in current and emerging Acute Pain market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Acute Pain. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging Acute Pain therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Acute Pain Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Acute Pain Market Report

• The Acute Pain market report covers a segment of key events, an executive summary, descriptive overview of Acute Pain, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Acute Pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Acute Pain market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Acute Pain market.

Acute Pain Market Report Insights

• Acute Pain Patient Population
• Acute Pain Therapeutic Approaches
• Acute Pain Pipeline Analysis
• Acute Pain Market Size
• Acute Pain Market Trends
• Existing and future Acute Pain Market Opportunity

Acute Pain Market Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Acute Pain Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL's feedback on approved and emerging Acute Pain therapies
• Key Cross Competition
• Conjoint analysis
• Acute Pain Drugs Uptake
• Key Acute Pain Market Forecast Assumptions

Acute Pain Market Report Assessment

• Current Acute Pain Treatment Practices
• Acute Pain Unmet Needs
• Acute Pain Pipeline Product Profiles
• Acute Pain Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the growth rate of the 7MM Acute Pain treatment market?
• What was the Acute Pain market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label Acute Pain therapies?
• How would the market drivers, barriers, and future opportunities affect the Acute Pain market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Acute Pain?
• How many companies are developing therapies for the treatment of Acute Pain?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Acute Pain therapies?

Reasons to buy:

• The Acute Pain market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Pain Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Acute Pain market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current Acute Pain patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Acute Pain companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Acute Pain market so that the upcoming Acute Pain companies can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Acute Pain Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Acute Pain in 2020 by drug class
• 3.2. Market Share (%) Distribution of Acute Pain in 2034 by drug class

4. Executive Summary of Acute Pain

5. Key Events

6. Acute Pain Epidemiology and Market Methodology

7. Disease Background and Overview: Acute Pain

• 7.1. Introduction
• 7.2. Difference Between Acute and Chronic Pain
• 7.3. The Transition of Acute Pain to Chronic Pain
• 7.4. Types of Acute Pain
• 7.5. Signs and Symptoms
• 7.6. Causes
• 7.7. Pathophysiology of Acute Pain
  • 7.7.1. Effects on key target organs.
• 7.8 Diagnosis
  • 7.8.1. Pain scales used for assessment of pain
  • 7.8.2. Diagnostic Guidelines
  • 7.8.3. Diagnostic algorithm
• 7.9. Treatment
  • 7.9.1. Nonpharmacological treatments for acute pain
  • 7.9.2. Pharmacological management of acute pain
  • 7.9.3. Treatment Guidelines
  • 7.9.4. Treatment algorithm

8. Acute Pain Patient Journey

9. Acute Pain Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: Acute Pain
• 9.3. The Total Incident Cases of Acute Pain in the 7MM
• 9.4. Total Diagnosed Incident Cases of Acute Pain in the 7MM
• 9.5. United States
  • 9.5.1. The Total Incident Cases of Acute Pain in the US
  • 9.5.2. Total Diagnosed Incident Cases of Acute Pain in the US
  • 9.5.3. Type-Specific Diagnosed Incident Cases of Acute Pain in the US
  • 9.5.4. Severity-Specific Diagnosed Incident Cases of Acute Pain in the US
  • 9.5.5. Total Treated Cases of Acute Pain in the US
• 9.6. EU4 and the UK
  • 9.6.1. The Total Incident Cases of Acute Pain in EU4 and the UK
  • 9.6.2. Total Diagnosed Incident Cases of Acute Pain in EU4 and the UK
  • 9.6.3. Type-Specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK
  • 9.6.4. Severity-Specific Diagnosed Incident Cases of Acute Pain in EU4 and the UK
  • 9.6.5. Total Treated Cases of Acute Pain in EU4 and the UK
• 9.7. Japan
  • 9.7.1. The Total Incident Cases of Acute Pain in Japan
  • 9.7.2. Total Diagnosed Incident Cases of Acute Pain in Japan
  • 9.7.3. Type-Specific Diagnosed Incident Cases of Acute Pain in Japan
  • 9.7.4. Severity-Specific Diagnosed Incident Cases of Acute Pain in Japan
  • 9.7.5. Total Treated Cases of Acute Pain in EU4 and the UK

10. Marketed Acute Pain Drugs

• 10.1. Key Cross Competition
• 10.2. POSIMIR (bupivacaine solution): Durect Corporation
  • 10.2.1. Product Description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other developmental activities
  • 10.2.4. Clinical Development
  • 10.2.5. Safety and Efficacy
• 10.3. SEGLENTIS (celecoxib and tramadol hydrochloride): Esteve/Kowa Pharmaceuticals/Mundipharma
  • 10.3.1. Product Description
  • 10.3.2. Regulatory milestones
  • 10.3.3. Other developmental activities
  • 10.3.4. Clinical Development
  • 10.3.5. Safety and Efficacy
• 10.4. DSUVIA (sufentanil): AcelRx Pharmaceuticals
  • 10.4.1. Product Description
  • 10.4.2. Regulatory milestones
  • 10.4.3. Other developmental activities
  • 10.4.4. Clinical Development
  • 10.4.5. Safety and Efficacy
• 10.5. ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
  • 10.5.1. Product Description
  • 10.5.2. Regulatory milestones
  • 10.5.3. Other developmental activities
  • 10.5.4. Clinical Development
  • 10.5.5. Safety and Efficacy
• 10.6. UBRELVY (ubrogepant): Allergan
  • 10.6.1. Product Description
  • 10.6.2. Regulatory milestones
  • 10.6.3. Other developmental activities
  • 10.6.4. Clinical Development
  • 10.6.5. Safety and Efficacy

11. Emerging Acute Pain Drugs

• 11.1. Key Cross Competition
• 11.2. Opiranserin (VVZ-149): Vivozon
  • 11.2.1. Product Description
  • 11.2.2. Other developmental activities
  • 11.2.3. Clinical development
  • 11.2.4. Safety and efficacy
• 11.3. TLC590 (ropivacaine liposomal): Taiwan Liposome Company (TLC)
  • 11.3.1. Product Description
  • 11.3.2. Other developmental activities
  • 11.3.3. Clinical development
  • 11.3.4. Safety and efficacy
• 11.4. VX-548 (suzetrigine): Vertex Pharmaceuticals
  • 11.4.1. Product Description
  • 11.4.2. Other developmental activities
  • 11.4.3. Clinical development
  • 11.4.4. Safety and efficacy

12. Acute Pain Market: 7MM Market Analysis

• 12.1. Key Findings
• 12.2. Acute Pain Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Acute Pain Market Forecast Assumptions
• 12.5. Total Market size of Acute Pain in the 7MM
• 12.6. Market Size of Acute Pain by Therapies in the 7MM
• 12.7. United States
  • 12.7.1. Total Market Size of Acute Pain in the US
  • 12.7.2. Market Size of Acute Pain by Therapies in the US
• 12.8. EU4 and the UK
  • 12.8.1. Total Market size of Acute Pain in EU4 and the UK
  • 12.8.2. Market Size of Acute Pain by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of Acute Pain in Japan
  • 12.9.2. Market Size of Acute Pain by Therapies in Japan

13. Acute Pain KOL Views

14. Acute Pain Unmet needs

15. Acute Pain SWOT Analysis

16. Acute Pain Market Access and Reimbursement

• 16.1. United States
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. Reimbursement Scenario and Key HTA Decisions in Acute Pain

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight